IP Library Granted Patent US 12,018,293
Granted Patent B2
US 12,018,293 · App. 17/042,125 · Granted Jun 25, 2024

Method for large-scale preparation of purified preparation of recombinant lentiviral vector at GMP grade

Inventors: Yi Hong (Shanghai, CN); Ting Yan (Shanghai, CN); Jiangguo Ying (Shanghai, CN); Haojie Zhang (Shanghai, CN); Li Zhang (Shanghai, CN); Fei Wang (Shanghai, CN); Dijun Zhao (Shanghai, CN); Luyi Zhang (Shanghai, CN)
Assignee: ABELZETA INC.
C12N7/02C12M47/02C12M47/12C12N7/00C12N15/101C12N15/1017C12N15/86C12N2740/15021C12N2740/15043C12N2740/15051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,018,293
App. No.
17/042,125
Granted
Jun 25, 2024
Kind
B2
Abstract

Provided is a method for large-scale preparation of a purified preparation of a recombinant lentiviral vector at the GMP grade. The method comprises: (a) providing raw material feed liquid to be purified that comprises recombinant viral vectors; (b) carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors; (c) optionally concentrating the filtrate to obtain a concentrated filtrate; (d) purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product comprising the recombinant viral vectors; and (e) subjecting the crude pure product obtained in the previous step to liquid exchange and elaborate purification to obtain the purified recombinant viral vectors.

Claims (20)

1. A method for large-scale purification of recombinant viral vectors, wherein the method comprises:

(a) providing a raw material comprising the recombinant viral vectors, wherein the raw material is a feed liquid, and wherein the feed liquid has a volume of no less than 20 liters;

(b) carrying out microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors, wherein the microfiltration treatment is conducted using a microfiltration hollow fiber column, wherein the microfiltration hollow fiber column comprises a microfiltration membrane with a cut-off value of 0.4 to 1.0 μm;

(c) concentrating the filtrate to obtain a concentrated filtrate, wherein the concentrating is conducted using an ultrafiltration hollow fiber column with a cut-off value of 200 K to 1000 K;

(d) purifying the filtrate by chromatography to obtain a crude product comprising the recombinant viral vectors; and

(e) subjecting the crude product to liquid exchange and purification, thereby obtaining purified recombinant viral vectors;

wherein the chromatography in step (d) is selected from the group consisting of anion chromatography, size exclusion chromatography, multi-mode composite resin chromatography, and combinations thereof.

2. The method of claim 1 , wherein the chromatography in step (d) comprises anion chromatography, followed by multi-mode composite chromatography.

3. The method of claim 1 , wherein after step (e), the method further comprises:

(f) subjecting the purified recombinant viral vectors to liquid exchange to obtain a virus freezing solution comprising the recombinant viral vectors; and

(g) sterilizing the virus freezing solution by filtration to obtain sterilized recombinant viral vectors.

4. The method of claim 1 , wherein the recombinant viral vectors comprise lentiviral vectors.

5. The method of claim 1 , wherein the filtrate obtained from step (b), or the concentrated filtrate obtained from step (c), is subjected to nuclease treatment before being purified by chromatography.

6. A purification device for performing the method of claim 1 , which comprises:

a microfiltration unit, wherein the microfiltration unit is used to perform microfiltration on the recombinant viral vectors to be purified to obtain a microfiltration filtrate;

a concentration unit, wherein the concentration unit is used to concentrate the microfiltration filtrate to obtain a concentrated filtrate; and

a chromatography purification unit, wherein the chromatography purification unit is used to perform chromatography purification on the concentrated filtrate to obtain purified recombinant lentiviral vectors.

7. The purification device of claim 6 , wherein the chromatography purification unit comprises a size exclusion chromatography unit and an anion chromatography unit.

8. The purification device of claim 6 , wherein the purification device further comprises:

a nuclease treatment unit, wherein the nuclease treatment unit comprises an adding device for adding a nuclease.

Assignments (6)
CHANGE OF NAME Recorded Jan 17, 2024
From: CELLULAR BIOMEDICINE GROUP, INC.
To: ABELZETA INC.
Reel/Frame 066340/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2022
From: CELLULAR BIOMEDICINE GROUP HK LTD.
To: CELLULAR BIOMEDICINE GROUP INC.
Reel/Frame 062175/0636 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2022
From: CELLULAR BIOMEDICINE GROUP HK LTD.
To: CELLULAR BIOMEDICINE GROUP INC.
Reel/Frame 062145/0499 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2021
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 058151/0760 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2021
From: WUXI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 058151/0871 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2020
From: HONG, YI; YAN, TING; YING, JIANGGUO; ZHANG, HAOJIE; ZHANG, LI; WANG, FEI; ZHAO, DIJUN; ZHANG, LUYI
To: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.; WUXI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
Reel/Frame 053913/0996 →
Priority Claims (1)
CN 201810264813.X · Mar 28, 2018 · national
Continuity (1)
Related Publication 20210009966A1 · Jan 14, 2021